PLoS ONE 7 , e39656 (2012)
However, these mechanisms may also cause significant muscle loss, gastrointestinal issues, and there is potential for malnutrition and loss of lean body mass in some individuals
The more options people have, the better, says Avlin Imaeda, MD, PhD, a Yale Medicine gastroenterologist who is board-certified in obesity medicine
GLP-1 adoption in India is a classic case of market readiness being overestimated
While Orforglipron and amycretin are still in the clinical trial phase, another promising candidate is further along
Each of these symptoms not only makes you less inclined to drink fluids but also causes your body to lose the fluids you do consume